No Data
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $12
Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger With Exscientia: Upside Potential Amidst Clinical Uncertainties
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
MARKET-TEST-DUMMY OP : NFA, JUST RISKY OPINIONS! BUT MAN! That chart is starting to look really good to me. I get it if you need to pull back some and consolidate or just consolidate and move forward is fine too. If it breaks that 9.50 range, I truly believe we will see 10+. The question is how long, right? So July last year it was 16ish and Feb this year it was 15ish. Are we beginning an up cycle? If I'm not mistaken NVDA took a small position here of 50 million bucks. The voices in my head....lol